Sarepta (SRPT) executive has shares withheld to pay RSU tax

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, had 948 shares of common stock withheld on March 11, 2026 to cover tax obligations linked to restricted stock units that vested from a grant dated March 10, 2025. The shares were valued at $17.03 each for this tax-withholding calculation. After this transaction, she directly holds 225,323 shares of common stock, indicating this was a small, routine adjustment related to equity compensation rather than an open-market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F(1)		948	D	$17.03	225,323	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report for Louise Rodino-Klapac?

Sarepta reported that Louise Rodino-Klapac had 948 common shares withheld to cover tax obligations. The withholding related to vesting of restricted stock units granted on March 10, 2025, and reflects routine equity compensation, not an open-market purchase or sale.

Was the Sarepta Therapeutics (SRPT) Form 4 transaction an open-market sale?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. 948 shares were withheld by Sarepta to satisfy tax liabilities from vested restricted stock units, a mechanical payroll-like event rather than a discretionary share sale.

How many Sarepta Therapeutics (SRPT) shares does Louise Rodino-Klapac hold after the Form 4 event?

After the tax-withholding transaction, Louise Rodino-Klapac directly holds 225,323 shares of Sarepta common stock. This indicates the 948 shares withheld for taxes represent a very small portion of her overall direct equity position in the company.

What price per share was used for the Sarepta (SRPT) tax-withholding on March 11, 2026?

The Form 4 lists a price of $17.03 per Sarepta common share for the 948 shares withheld. This figure is used to calculate the value of stock withheld to satisfy income tax obligations associated with the vesting restricted stock units.

What was the source of the shares involved in the Sarepta (SRPT) tax-withholding transaction?

The shares relate to restricted stock units granted on March 10, 2025, that later vested. When these RSUs vested, Sarepta withheld 948 resulting common shares to cover tax liabilities, as disclosed in the Form 4 footnote.